RecruitingNot ApplicableNCT06363981

Multisite rTMS for Mood, Cognitive Impairment and Other Symptoms of Depression

Multisite Repetitive Transcranial Magnetic Stimulation for Mood, Cognitive Impairment, Anhedonia and Disordered Sleep in Depressive Disorder


Sponsor

Jakub Antczak

Enrollment

90 participants

Start Date

May 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Depressed mood is the main symptom of depression, but other symptoms like cognitive impairment, anhedonia or sleep disorders may also contribute to patients suffering and are difficult to treat. rTMS is a relatively novel treatment option, whose therapeutic potential is still investigated and optimized. The aim of this study is to assess the effect of rTMS applied over two stimulation sites on cognitive impairment, anhedonia and sleep disorders in depression.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

  • severe or moderate depressive episode (according to international classification of diseases (ICD)-10) without psychotic symptoms at the time of inclusion
  • Hamilton Depression Rating Scale between between 20 and 35 points at inclusion
  • The score in the Athens Insomnia Scale eight or more
  • The score of three or more points in items 4 and 21 of the Beck Depressions Inventory 2
  • Complaining about problems with memory and concentration timely related with the onset of depression

Exclusion Criteria3

  • Contraindications to transcranial magnetic stimulation, including ferromagnetic elements in head, pregnancy and epilepsy
  • Psychotic symptoms at the time of inclusion
  • Suicidal ideations and/or attempts within three months prior to inclusion

Interventions

DEVICEActive rTMS over the left DLPFC and over the left DMPFC

Active rTMS over the left DLPFC and over the left DMPFC to induce the long term potentiation of stimulated areas.

DEVICEActive rTMS over the left DLPFC

Active rTMS over the left DLPFC to induce the long term potentiation of stimulated area.

DEVICESham rTMS

Sham rTMS over the left DLPFC or over the left DLPFC and over the left DMPFC for placebo.


Locations(1)

The Education of Research and Development Center, Babinski Clinical Hospital

Krakow, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06363981


Related Trials